BioCryst Pharmaceuticals

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a biotechnology company that focuses on the development of novel oral and small-molecule drugs for the treatment of rare diseases. The company is headquartered in Durham, North Carolina, United States.

History

BioCryst Pharmaceuticals was founded in 1986 by Charles E. Bugg, Ph.D., and John A. Montgomery, Ph.D. The company initially focused on the design and development of small-molecule drugs using structure-based drug design techniques. Over the years, BioCryst has evolved to focus on developing treatments for rare diseases, particularly those involving the immune system and genetic disorders.

Products

BioCryst Pharmaceuticals has developed several products, including:

• Orladeyo (berotralstat): An oral medication approved for the prevention of hereditary angioedema (HAE) attacks in patients 12 years and older.
• Peramivir: An antiviral drug used for the treatment of influenza. It is marketed under the brand name Rapivab.
• BCX9930: An investigational oral Factor D inhibitor for the treatment of complement-mediated diseases.

Research and Development

BioCryst Pharmaceuticals is actively involved in research and development to expand its pipeline of drugs. The company focuses on rare diseases, including:

• Hereditary Angioedema (HAE): A genetic disorder characterized by recurrent episodes of severe swelling.
• Complement-mediated diseases: Disorders caused by dysregulation of the complement system, part of the immune system.

Collaborations and Partnerships

BioCryst Pharmaceuticals has engaged in various collaborations and partnerships to advance its research and development efforts. These collaborations help the company leverage external expertise and resources to accelerate the development of its drug candidates.

Related pages

• Biotechnology
• Pharmaceutical industry
• Rare disease
• Hereditary angioedema
• Antiviral drug